Did you know that a simple nutraceutical compound, Homoharringtonine (HHT), derived from Cephalotaxus harringtonia, plays a pivotal role in cancer treatment?
Since the 1970s, Homoharringtonine (HHT), sourced from Cephalotaxus harringtonia, has been a cornerstone of Chinese medicine for treating acute myeloid leukemia (AML). The SCMC-AML-2009 trial illuminates its remarkable efficacy, particularly in pediatric AML patients under two years old. Compared to anthracycline-based treatments, the Homoharringtonine-based regimen showed significantly higher 5-year event-free survival (88.0%±6.5% vs. 60.2%±9.6% P=0.024). Moreover, patients experienced reduced hematologic toxicity and infection risks during chemotherapy, underscoring its effectiveness and safety in AML treatment for this age group.
Source: https://journal.hep.com.cn/fmd/EN/10.1007/s11684-018-0658-4
